Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers

Chinese Medical Journal

Volumn 121, Issue 13, 2008, Pages 1215-1219

  Hua, Cong Xiao ^a   Li, Yi Shi ^a   Liu, Yu Qing ^a   Liu, Hong ^a   Li, Na ^a   Wu, Ying ^a   Xu, Li ^a   Huang, Yi Ling ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Gene expression; Leukocytes; Microarray analysis; Rosuvastatin

Indexed keywords

ATM PROTEIN; C REACTIVE PROTEIN; CASPASE 8; CYTOKINE; CYTOKINE RECEPTOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 8 RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN S100B; ROSUVASTATIN; TRIACYLGLYCEROL; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; APOPTOSIS; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CYTOLOGY; DNA MICROARRAY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FIBRINOGEN BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE; LIPID BLOOD LEVEL; MALE; MICROARRAY ANALYSIS; MORNING DOSAGE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PLEIOTROPY; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VOLUNTEER; BLOOD; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION;

ADULT; CASPASE 8; FLUOROBENZENES; GENE EXPRESSION PROFILING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES; LIPIDS; MALE; POLYMERASE CHAIN REACTION; PYRIMIDINES; RECEPTORS, INTERLEUKIN-8; SULFONAMIDES;

EID: 50549098244     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200807010-00013     Document Type: Article

References (26)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357,
3. Briel M, Nordmann AJ, Bucher HC. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses, Carr Opin Lipidol 2005; 16: 601-605.
4. Michelena HI, Osorio LA, Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol 2005; 101: 111-114.
5. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26: 1388-1399.
6. Gao RL. The efficacy and safety of rosuvastatin on treating patients with hypercholestrolemia in Chinese: a randomized, double-blind, multi-center clinical trial. Chin J Cardiol (Chin) 2007; 35: 207-211.
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 11139-43.
8. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003; 108: 1368-1374.
9. Monetti M, Canavesi M, Camera M, Parente R, Paoletti R, Tremoli E, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 2007; 55: 441-449.
10. Li W, Asagami T_ Matsushita H, Lee KH. Tsao PS. Rosuvastatin, attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J Pharmacol Exp Ther 2005; 313: 557-562.
11. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005; 66: 462-471.
12. Furman C, Copin C, Kandoussi M, Davidson F, Moreau M, McTaggiart F, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004; 174: 93-98.
13. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109: 11120-26.
14. Ardigo D, Gaillard CA, Braam B. Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clin Chem Lab Med 2007; 45: 1109-1120.
15. Burczynski ME, Donner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 2006; 7: 187-202.
16. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, et al. Performance comparison of one-color and two-color platforms, within the MicroArray Quality Control (MAQC) project. Nat Biotechnol 2006; 24: 1140-1150.
17. Yang YH, Dudoit S, Lim P. Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30: e15.
18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121.
19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
20. Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997; 38: 1496-1500.
21. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: 112-10.
22. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-1566.
23. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000; 21: 129-137.
24. Wu D, Yang H, Xiang W, Zhou L, Shi M, Julies G, et al. Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. J Lipid Res 2005; 46: 1380-1387.
25. Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000; 152: 217-227,
26. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007; 85: 1373-1380.